Table 4.
Combination of histone modification enzyme inhibitors.
| Epi-drug | Combination | Clinical stage | Cancer specificity | NCT number |
|---|---|---|---|---|
| EZH2 inhibitor tazemetostat | Cyclophosphamide/doxorubicin/ oncovin/prednisone | Phase III | EZH2 mutant DLBCL | NCT04204941 |
| HDAC inhibitor vorinostat | Olaparid | Phase I | Breast cancer | NCT03742245 |
| HDAC inhibitor mocetinostat | Gemcitabine | Phase II | Metastatic leiomyosarcoma | NCT02303262 |
| HDAC inhibitor depsipeptide/FK228 | Alisertib/pralatrexate/gemcitabine | Phase III | Relapsed PTCL | NCT01482962 |
| HDAC inhibitor resminostat | Sorafenib | Phase I and II | Hepatocellular carcinoma | NCT02400788 |
| DNMT inhibitor disulfiram | Chelated zinc | Phase II | Melamoma | NCT02101008 |
| DNMT inhibitor azacytidine | Cytarabine | Phase III | Acute myeloid leukemia | NCT01839240 |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; DNMT, DNA methyltransferases; HDAC, histone deacetylase; PTCL, peripheral T-cell lymphoma.